Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis

Part of paid clinical trials in St Louis, Missouri.

Sponsor
Eidos Therapeutics, a BridgeBio company
Study ID
NCT07695701
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

  • Amyloid Cardiomyopathy
  • Amyloidosis
  • Transthyretin Amyloidosis
  • Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Acoramidis (AG10) oral tablet — DRUG
    Study drug is defined as acoramidis 712 mg (equivalent to 800 mg acoramidis hydrochloride) taken orally twice daily for 36 months of open label treatment.

Study Details

The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.

Key Dates

First listed
Jul 10, 2026
Start date
Jul 31, 2026
Status verified
Jul 2026
Primary completion
Aug 31, 2030
Completion
Nov 30, 2030

Study Design

Enrollment
150 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Acoramidis (AG10)
    Open-label study where all participants will receive acoramidis (AG10) during the study

Primary Outcome Measure

To assess the effect of acoramidis on cardiac function improvement by CMR in participants with ATTR-CM. [ Time Frame: Month 36 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Washington University in St. LouisSt LouisMissouri63110-

Find similar trials in St Louis, MO

By research site
Washington University in St. Louis· St Louis, MO

Related Studies